Korea Q1 Roundup: Mixed Earnings Amid M&A, Prescription Sales
Boryung Blasts Into Space
Large Korean pharma firms’ first-quarter earnings were mostly mixed on a range of diverse factors such as solid prescription sales and impacts from acquisitions, with some even looking to space for new business opportunities.
You may also be interested in...
South Korea designates two more global innovative products for support under a new fast track system, in a move set to speed up patient access to novel therapies.
Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.
A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.